A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Grants and Contracts Details

StatusFinished
Effective start/end date10/28/15 → 9/30/17

Funding

  • Rho Incorporated: $84,740.00